Symbicort® COPD (budesonide/formoterol)

Symbicort® (budesonide/formoterol) Turbohaler® and Symbicort® pMDI are combinations of an inhaled corticosteroid and a long-acting β2-agonist 

Chronic obstructive pulmonary disease (COPD) and Symbicort®

Exacerbation reduction

Symbicort® Turbohaler® reduced the incidence of severe exacerbations* by 23% vs formoterol4



This study demonstrated that Symbicort® Turbohaler® increased FEV1 (co-primary endpoint) by 1% vs formoterol (n=208 and n=201 respectively; p=NS) and demonstrated a reduction in severe exacerbations* with Symbicort® Turbohaler® 200/6 μg vs formoterol 6 μg: 1.42 vs 1.84 severe exacerbations* per patient per year, respectively.4

This was a 12-month, randomised, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 years, mean FEV1 36% predicted normal). Patients received 2 inhalations twice daily of either: Symbicort®Turbohaler® 200/6µg (n=208); budesonide 200 µg (n=198); formoterol 6µg (n=201); or placebo (n=205). Primary efficacy variables: number of severe exacerbations* and FEV1.4

*Severe exacerbations were defined as the use of oral steroids and/or antibiotics and/or hospitalisations due to respiratory symptoms.4

Doses are expressed as metered doses.